Published in Biomed Rep on November 29, 2013
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis (2006) 4.29
Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med (1999) 2.82
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66
Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock (1998) 2.51
Low levels of protein C are associated with poor outcome in severe sepsis. Chest (2001) 2.05
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut (2000) 1.86
Factors influencing mortality in acute pancreatitis: can we alter them? J Clin Gastroenterol (2005) 1.82
Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg (2000) 1.77
The role of infection in acute pancreatitis. Gut (1999) 1.66
The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med (2002) 1.66
Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med (1998) 1.65
Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol (2005) 1.65
MODS/SIRS: result of an overwhelming inflammatory response? World J Surg (1996) 1.57
Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) (2006) 1.47
Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res (1990) 1.45
Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des (2003) 1.42
Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol (2002) 1.40
Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) (2007) 1.25
Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol (2007) 1.24
Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg (1996) 1.23
Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis. Pancreas (2000) 1.23
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) (2007) 1.19
Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol (2007) 1.17
Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology (Oxford) (2007) 1.16
C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14
Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology (Oxford) (2005) 1.06
Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol (1998) 1.03
Cytokines and acute pancreatitis. Baillieres Best Pract Res Clin Gastroenterol (1999) 0.99
The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis (2007) 0.94
Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood (1990) 0.92
Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med (2004) 0.92
Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis (2005) 0.90
Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group. J Trauma (2000) 0.89
Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res (1997) 0.87
Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol (2004) 0.87
Role of endogenous glucocorticoid metabolism in human acute pancreatitis. Crit Care Med (2006) 0.84
Severe acute pancreatitis: overall and early versus late mortality in intensive care units. Pancreas (2009) 0.83
Early rheumatoid arthritis. Br Med Bull (2007) 0.83
Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Shock (2005) 0.83
Intestine-specific overexpression of IL-10 improves survival in polymicrobial sepsis. Shock (2008) 0.83
Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol (2008) 0.83
[The pathogenesis of the systemic inflammatory response syndrome and compensatory antiinflammatory response syndrome following surgical stress]. Nihon Geka Gakkai Zasshi (2003) 0.82
The anti-inflammatory effect of methylprednisolone occurs down-stream of nuclear factor-kappaB DNA binding in acute pancreatitis. Eur J Pharmacol (2003) 0.82
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. BioDrugs (2002) 0.81
Treatment of experimental acute pancreatitis with 5-flourouracil (5-FU). Am J Surg (1973) 0.80
Production and purification of bovine monocyte-derived interleukin 1. Vet Immunol Immunopathol (1989) 0.80
Protective effect of bactericidal/permeability-increasing protein in mice with E. coli sepsis. Chin J Traumatol (1998) 0.79
Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol (2006) 0.79
Clinical value of cytokine antagonists in infectious complications. Res Commun Mol Pathol Pharmacol (1997) 0.78
5-Fluorouracil in the treatment of acute pancreatitis. Am J Surg (1983) 0.78
A novel recombinant snake venom metalloproteinase from Agkistrodon acutus protects against taurocholate-induced severe acute pancreatitis in rats. Biochimie (2010) 0.77
[SIRS and CARS: discussion based on the pathologic condition of acute pancreatitis]. Rinsho Byori (2000) 0.77
[Cytokine imbalance in critically ill patients: SIRS and CARS]. Nihon Geka Gakkai Zasshi (1999) 0.76
A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats . Crit Care Med (1997) 0.75